On the public citation graph
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
0 signed · 319 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1521-3773(20020816)41:16<2937::aid-anie2937>3.0.co;2-jopenalex-snapshot
Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with Target Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid…
inferredcites →https://doi.org/10.1002/anie.200352006openalex-snapshot
A Metallopeptide Assembly of the HIV‐1 gp41 Coiled Coil Is an Ideal Receptor in Fluorescence Detection of Ligand Binding
inferredcites →https://doi.org/10.1002/cmdc.201000289openalex-snapshot
Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41
inferredcites →https://doi.org/10.1002/psc.2802openalex-snapshot
Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin
inferredcites →https://doi.org/10.1006/bbrc.1993.2078openalex-snapshot
Inhibition of HIV-1 Infection by a Fusion Domain Binding Peptide from the HIV-1 Envelope Glycoprotein GP41
inferredcites →https://doi.org/10.1006/viro.1997.8547openalex-snapshot
A Human IgG1 (b12) Specific for the CD4 Binding Site of HIV-1 Neutralizes by Inhibiting the Virus Fusion Entry Process, but b12 Fab Neutralizes by Inhibiting a Postfusion Event
inferredcites →https://doi.org/10.1007/s00705-016-2942-4openalex-snapshot
VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice
inferredcites →https://doi.org/10.1007/s00705-017-3514-yopenalex-snapshot
GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4+ T lymphocyte count
inferredcites →https://doi.org/10.1007/s00726-016-2325-xopenalex-snapshot
A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41
inferredcites →https://doi.org/10.1007/s11481-016-9681-xopenalex-snapshot
Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor
inferredcites →https://doi.org/10.1007/s11684-017-0589-5openalex-snapshot
Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses
inferredcites →https://doi.org/10.1007/s11908-010-0142-zopenalex-snapshot
Current Views on the Pathophysiology of GB Virus C Coinfection with HIV-1 Infection
inferredcites →https://doi.org/10.1016/0092-8674(86)90778-6openalex-snapshot
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
inferredcites →https://doi.org/10.1016/j.antiviral.2010.04.011openalex-snapshot
Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat
inferredcites →https://doi.org/10.1016/j.antiviral.2010.08.004openalex-snapshot
Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
inferredcites →https://doi.org/10.1016/j.bbagen.2016.02.008openalex-snapshot
Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor
inferredcites →https://doi.org/10.1016/j.bbamem.2012.07.020openalex-snapshot
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain
inferredcites →https://doi.org/10.1016/j.bbamem.2014.10.033openalex-snapshot
Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition
inferredcites →https://doi.org/10.1016/j.bbrc.2005.05.037openalex-snapshot
Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeutics
inferredcites →https://doi.org/10.1016/j.bmc.2007.03.064openalex-snapshot
Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins
inferredcites →https://doi.org/10.1016/j.bmc.2008.09.018openalex-snapshot
Identification of minimal sequence for HIV-1 fusion inhibitors
inferredcites →https://doi.org/10.1016/j.cell.2007.02.042openalex-snapshot
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
inferredcites →https://doi.org/10.1016/j.cell.2009.02.046openalex-snapshot
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
inferredcites →https://doi.org/10.1016/j.cell.2014.09.009openalex-snapshot
Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies
inferredcites →https://doi.org/10.1016/j.cell.2016.04.050openalex-snapshot
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
inferredcites →https://doi.org/10.1016/j.cell.2016.05.024openalex-snapshot
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
inferredcites →https://doi.org/10.1016/j.celrep.2014.04.001openalex-snapshot
Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike
inferredcites →https://doi.org/10.1016/j.colsurfb.2017.01.032openalex-snapshot
Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies
inferredcites →https://doi.org/10.1016/j.ebiom.2016.06.037openalex-snapshot
Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry
inferredcites →https://doi.org/10.1016/j.ejmech.2014.09.020openalex-snapshot
A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1
inferredcites →https://doi.org/10.1016/j.imbio.2008.04.005openalex-snapshot
Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors
inferredcites →https://doi.org/10.1016/j.imbio.2012.01.007openalex-snapshot
Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell–cell fusion assay
inferredcites →https://doi.org/10.1016/j.immuni.2014.04.008openalex-snapshot
Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers
inferredcites →https://doi.org/10.1016/j.immuni.2014.04.009openalex-snapshot
Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers
inferredcites →https://doi.org/10.1016/j.immuni.2016.10.027openalex-snapshot
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
inferredcites →https://doi.org/10.1016/j.intimp.2017.08.016openalex-snapshot
Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges
inferredcites →https://doi.org/10.1016/j.jcis.2011.04.053openalex-snapshot
Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C
inferredcites →https://doi.org/10.1016/j.jconrel.2012.06.002openalex-snapshot
Improvement of drug safety by the use of lipid-based nanocarriers
inferredcites →https://doi.org/10.1016/j.jinf.2017.03.006openalex-snapshot
Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains
inferredcites →https://doi.org/10.1016/j.jmb.2008.06.069openalex-snapshot
Combinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope Glycoprotein
inferredcites →https://doi.org/10.1016/j.molcel.2010.02.012openalex-snapshot
Topological Layers in the HIV-1 gp120 Inner Domain Regulate gp41 Interaction and CD4-Triggered Conformational Transitions
inferredcites →https://doi.org/10.1016/j.omtn.2017.04.017openalex-snapshot
Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI T45
inferredcites →https://doi.org/10.1016/j.virol.2008.04.005openalex-snapshot
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics
inferredcites →https://doi.org/10.1016/j.virol.2008.12.031openalex-snapshot
HIV entry in macrophages is dependent on intact lipid rafts
inferredcites →https://doi.org/10.1016/j.virol.2013.07.019openalex-snapshot
Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN
inferredcites →https://doi.org/10.1016/s0042-6822(03)00521-xopenalex-snapshot
Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains
inferredcites →https://doi.org/10.1016/s0092-8674(00)80205-6openalex-snapshot
Core Structure of gp41 from the HIV Envelope Glycoprotein
inferredcites →https://doi.org/10.1016/s0092-8674(03)00508-7openalex-snapshot
Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120
inferredcites →https://doi.org/10.1016/s0190-9622(03)02099-1openalex-snapshot
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
inferredcites →https://doi.org/10.1016/s0929-6646(10)60029-0openalex-snapshot
HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
inferredcites →https://doi.org/10.1016/s1473-3099(11)70249-3openalex-snapshot
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
inferredcites →https://doi.org/10.1016/s2352-3018(16)30119-9openalex-snapshot
Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey
inferredcites →https://doi.org/10.1021/bc049960ropenalex-snapshot
Synthetic Bivalent CD4-Mimetic Miniproteins Show Enhanced Anti-HIV Activity over the Monovalent Miniprotein
inferredcites →https://doi.org/10.1021/bi035088iopenalex-snapshot
Mode of Action for Linear Peptide Inhibitors of HIV-1 gp120 Interactions
inferredcites →https://doi.org/10.1021/bi051120sopenalex-snapshot
Protein Minimization of the gp120 Binding Region of Human CD4
inferredcites →https://doi.org/10.1021/bi1005267openalex-snapshot
Alanine Scanning Mutagenesis of HIV-1 gp41 Heptad Repeat 1: Insight into the gp120−gp41 Interaction
inferredcites →https://doi.org/10.1021/bi7001289openalex-snapshot
Protein Design of a Bacterially Expressed HIV-1 gp41 Fusion Inhibitor
inferredcites →https://doi.org/10.1021/jm000403+openalex-snapshot
Short Peptides with Induced β-Turn Inhibit the Interaction between HIV-1 gp120 and CD4
inferredcites →https://doi.org/10.1021/jm070814ropenalex-snapshot
Structural Determinants for Affinity Enhancement of a Dual Antagonist Peptide Entry Inhibitor of Human Immunodeficiency Virus Type-1
inferredcites →https://doi.org/10.1021/jm100452copenalex-snapshot
Effect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infection
inferredcites →https://doi.org/10.1021/jm4002988openalex-snapshot
Interfacial Cavity Filling To Optimize CD4–Mimetic Miniprotein Interactions with HIV-1 Surface Glycoprotein
inferredcites →https://doi.org/10.1038/31405openalex-snapshot
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
inferredcites →https://doi.org/10.1038/331084a0openalex-snapshot
Soluble CD4 molecules neutralize human immunodeficiency virus type 1
inferredcites →https://doi.org/10.1038/384179a0openalex-snapshot
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
inferredcites →https://doi.org/10.1038/cmi.2015.38openalex-snapshot
Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1
inferredcites →https://doi.org/10.1038/emi.2016.86openalex-snapshot
An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene
inferredcites →https://doi.org/10.1038/gt.2013.70openalex-snapshot
A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells
inferredcites →https://doi.org/10.1038/nature04055openalex-snapshot
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion
inferredcites →https://doi.org/10.1038/nature05580openalex-snapshot
Structural definition of a conserved neutralization epitope on HIV-1 gp120
inferredcites →https://doi.org/10.1038/nature07159openalex-snapshot
Molecular architecture of native HIV-1 gp120 trimers
inferredcites →https://doi.org/10.1038/nature10373openalex-snapshot
Broad neutralization coverage of HIV by multiple highly potent antibodies
inferredcites →https://doi.org/10.1038/nature11544openalex-snapshot
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
inferredcites →https://doi.org/10.1038/nature12744openalex-snapshot
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
inferredcites →https://doi.org/10.1038/nature12746openalex-snapshot
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
inferredcites →https://doi.org/10.1038/nature13601openalex-snapshot
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
inferredcites →https://doi.org/10.1038/nature14411openalex-snapshot
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
inferredcites →https://doi.org/10.1038/nature17677openalex-snapshot
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
inferredcites →https://doi.org/10.1038/nature18929openalex-snapshot
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
inferredcites →https://doi.org/10.1038/nature23010openalex-snapshot
Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike
inferredcites →https://doi.org/10.1038/nbt768openalex-snapshot
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
inferredcites →https://doi.org/10.1038/ncomms4067openalex-snapshot
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
inferredcites →https://doi.org/10.1038/ncomms9167openalex-snapshot
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
inferredcites →https://doi.org/10.1038/nm.4268openalex-snapshot
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
inferredcites →https://doi.org/10.1038/nmicrobiol.2016.199openalex-snapshot
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability
inferredcites →https://doi.org/10.1038/nsb1295-1075openalex-snapshot
A trimeric structural domain of the HIV-1 transmembrane glycoprotein
inferredcites →https://doi.org/10.1038/s41586-018-0531-2openalex-snapshot
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
inferredcites →https://doi.org/10.1038/s41586-018-0804-9openalex-snapshot
Structural basis of coreceptor recognition by HIV-1 envelope spike
inferredcites →https://doi.org/10.1038/s41591-018-0186-4openalex-snapshot
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
inferredcites →https://doi.org/10.1038/srep13028openalex-snapshot
Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
inferredcites →https://doi.org/10.1038/srep31983openalex-snapshot
Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations
inferredcites →https://doi.org/10.1039/c8md00508gopenalex-snapshot
Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity
inferredcites →https://doi.org/10.1042/bj20140189openalex-snapshot
Early and late HIV-1 membrane fusion events are impaired by sphinganine lipidated peptides that target the fusion site
inferredcites →https://doi.org/10.1056/nejmoa010398openalex-snapshot
Infection with GB Virus C and Reduced Mortality among HIV-Infected Patients
inferredcites →https://doi.org/10.1056/nejmoa035026openalex-snapshot
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
inferredcites →https://doi.org/10.1056/nejmoa035211openalex-snapshot
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
inferredcites →https://doi.org/10.1073/pnas.0308527100openalex-snapshot
Structural basis of tyrosine sulfation and V H -gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120
inferredcites →https://doi.org/10.1073/pnas.0506927102openalex-snapshot
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
inferredcites →https://doi.org/10.1073/pnas.0701478104openalex-snapshot
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
inferredcites →https://doi.org/10.1073/pnas.0802666105openalex-snapshot
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249
inferredcites →https://doi.org/10.1073/pnas.0805297105openalex-snapshot
Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers
inferredcites →https://doi.org/10.1073/pnas.0807335105openalex-snapshot
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
inferredcites →https://doi.org/10.1073/pnas.0901007106openalex-snapshot
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
inferredcites →https://doi.org/10.1073/pnas.0911004107openalex-snapshot
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility
inferredcites →https://doi.org/10.1073/pnas.1203183109openalex-snapshot
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission
inferredcites →https://doi.org/10.1073/pnas.1214785109openalex-snapshot
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
inferredcites →https://doi.org/10.1073/pnas.1217207109openalex-snapshot
Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
inferredcites →https://doi.org/10.1073/pnas.1304985110openalex-snapshot
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1
inferredcites →https://doi.org/10.1073/pnas.1309215110openalex-snapshot
Computational analysis of anti–HIV-1 antibody neutralization panel data to identify potential functional epitope residues
inferredcites →https://doi.org/10.1073/pnas.1315295110openalex-snapshot
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
inferredcites →https://doi.org/10.1073/pnas.1615939113openalex-snapshot
Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop
inferredcites →https://doi.org/10.1073/pnas.201392898openalex-snapshot
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
inferredcites →https://doi.org/10.1073/pnas.87.17.6574openalex-snapshot
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
inferredcites →https://doi.org/10.1073/pnas.89.21.10537openalex-snapshot
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
inferredcites →https://doi.org/10.1073/pnas.96.23.13091openalex-snapshot
Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein
inferredcites →https://doi.org/10.1074/jbc.c100317200openalex-snapshot
Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity
inferredcites →https://doi.org/10.1074/jbc.m007228200openalex-snapshot
A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry
inferredcites →https://doi.org/10.1074/jbc.m110.101170openalex-snapshot
Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides
inferredcites →https://doi.org/10.1074/jbc.m111.241992openalex-snapshot
A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability
inferredcites →https://doi.org/10.1074/jbc.m111.251025openalex-snapshot
Probing the HIV gp120 Envelope Glycoprotein Conformation by NMR
inferredcites →https://doi.org/10.1074/jbc.m111.317883openalex-snapshot
Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide
inferredcites →https://doi.org/10.1074/jbc.m112.399402openalex-snapshot
A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01
inferredcites →https://doi.org/10.1074/jbc.m114.591826openalex-snapshot
Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation
inferredcites →https://doi.org/10.1074/jbc.m201453200openalex-snapshot
Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41
inferredcites →https://doi.org/10.1074/jbc.m411122200openalex-snapshot
Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp.
inferredcites →https://doi.org/10.1074/jbc.m411141200openalex-snapshot
Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120
inferredcites →https://doi.org/10.1074/jbc.m602732200openalex-snapshot
A Tyrosine-sulfated Peptide Derived from the Heavy-chain CDR3 Region of an HIV-1-neutralizing Antibody Binds gp120 and Inhibits HIV-1 Infection
inferredcites →https://doi.org/10.1074/jbc.m609148200openalex-snapshot
HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains
inferredcites →https://doi.org/10.1074/jbc.m800200200openalex-snapshot
Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor
inferredcites →https://doi.org/10.1074/jbc.m801083200openalex-snapshot
Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process
inferredcites →https://doi.org/10.1074/jbc.m805536200openalex-snapshot
Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor
inferredcites →https://doi.org/10.1074/jbc.ra118.001729openalex-snapshot
Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
inferredcites →https://doi.org/10.1080/07391102.1997.10508958openalex-snapshot
A Trimeric Structural Subdomain of the HIV-1 Transmembrane Glycoprotein
inferredcites →https://doi.org/10.1080/19420862.2016.1160180openalex-snapshot
Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1
inferredcites →https://doi.org/10.1084/jem.20120423openalex-snapshot
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
inferredcites →https://doi.org/10.1084/jem.20130221openalex-snapshot
Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies
inferredcites →https://doi.org/10.1086/315698openalex-snapshot
Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected Adults
inferredcites →https://doi.org/10.1086/379810openalex-snapshot
Enfuvirtide (T‐20) Cross‐Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide
inferredcites →https://doi.org/10.1086/511037openalex-snapshot
Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy
inferredcites →https://doi.org/10.1089/088922200750054765openalex-snapshot
Monoclonal Antibodies That Bind to the Core of Fusion-Active Glycoprotein 41
inferredcites →https://doi.org/10.1089/088922202760072294openalex-snapshot
The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults
inferredcites →https://doi.org/10.1089/aid.1995.11.533openalex-snapshot
Expression and Characterization of CD4-IgG 2 , a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates
inferredcites →https://doi.org/10.1089/aid.1997.13.575openalex-snapshot
Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates
inferredcites →https://doi.org/10.1089/aid.2017.0063openalex-snapshot
A 2–4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01
inferredcites →https://doi.org/10.1093/jac/dkh141openalex-snapshot
Cutaneous injection site reactions to long-term therapy with enfuvirtide
inferredcites →https://doi.org/10.1093/jac/dkn042openalex-snapshot
CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides
inferredcites →https://doi.org/10.1093/jac/dkt230openalex-snapshot
An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides
inferredcites →https://doi.org/10.1093/jac/dkt529openalex-snapshot
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure
inferredcites →https://doi.org/10.1096/fj.09-151704openalex-snapshot
Virus‐cell and cell‐cell fusion mediated by the HIV‐1 envelope glycoprotein is inhibited by short gp41 N‐terminal membrane‐anchored peptides lacking the critical pocket domain
inferredcites →https://doi.org/10.1096/fj.12-215111openalex-snapshot
Sphingopeptides: dihydrosphingosine‐based fusion inhibitors against wild‐type and enfuvirtide‐resistant HIV‐1
inferredcites →https://doi.org/10.1096/fj.12-222547openalex-snapshot
Short‐peptide fusion inhibitors with high potency against wild‐type and enfuvirtide‐resistant HIV‐1
inferredcites →https://doi.org/10.1097/00002030-199506000-00001openalex-snapshot
Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
inferredcites →https://doi.org/10.1097/00002030-200012220-00002openalex-snapshot
Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice
inferredcites →https://doi.org/10.1097/00002371-199405000-00003openalex-snapshot
Plasma Pharmacokinetics and Biological Activity of a Human Immunodeficiency Virus Type 1 Neutralizing Human Monoclonal Antibody, F105, in Cynomolgus Monkeys
inferredcites →https://doi.org/10.1097/01.aids.0000247112.36091.f8openalex-snapshot
An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli
inferredcites →https://doi.org/10.1097/qad.0000000000000498openalex-snapshot
Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket
inferredcites →https://doi.org/10.1097/qad.0000000000000683openalex-snapshot
Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41
inferredcites →https://doi.org/10.1097/qad.0000000000001073openalex-snapshot
Development of potent and long-acting HIV-1 fusion inhibitors
inferredcites →https://doi.org/10.1097/qad.0000000000001415openalex-snapshot
A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity
inferredcites →https://doi.org/10.1097/qad.0000000000001979openalex-snapshot
Structural and functional characterization of HIV-1 cell fusion inhibitor T20
inferredcites →https://doi.org/10.1097/qad.0000000000002208openalex-snapshot
Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41
inferredcites →https://doi.org/10.1097/qad.0b013e32803277c7openalex-snapshot
HIV entry inhibition by the envelope 2 glycoprotein of GB virus C
inferredcites →https://doi.org/10.1097/qad.0b013e3283101260openalex-snapshot
Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates
inferredcites →https://doi.org/10.1097/qad.0b013e328325a4cdopenalex-snapshot
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
inferredcites →https://doi.org/10.1097/qad.0b013e32835cfca5openalex-snapshot
Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex
inferredcites →https://doi.org/10.1097/qai.0000000000000265openalex-snapshot
Synergistic Effect Resulting From Combinations of a Bifunctional HIV-1 Antagonist With Antiretroviral Drugs
inferredcites →https://doi.org/10.1097/qai.0000000000000283openalex-snapshot
Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies
inferredcites →https://doi.org/10.1097/qai.0000000000000851openalex-snapshot
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses
inferredcites →https://doi.org/10.1098/rstb.1993.0136openalex-snapshot
The role of CD4 in HIV binding and entry
inferredcites →https://doi.org/10.1099/jgv.0.000299openalex-snapshot
Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-N and Galanthus nivalis agglutinin
inferredcites →https://doi.org/10.1099/vir.0.033092-0openalex-snapshot
Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin
inferredcites →https://doi.org/10.1111/j.1365-3083.1995.tb03528.xopenalex-snapshot
Enhancement of Infectivity of a Non‐Syncytium Inducing HIV‐1 by sCD4 and by Human Antibodies that Neutralize Syncytium Inducing HIV‐1
inferredcites →https://doi.org/10.1126/sciadv.aav4580openalex-snapshot
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
inferredcites →https://doi.org/10.1126/science.1057453openalex-snapshot
Protein Design of an HIV-1 Entry Inhibitor
inferredcites →https://doi.org/10.1126/science.1111781openalex-snapshot
Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies
inferredcites →https://doi.org/10.1126/science.1118398openalex-snapshot
Structure of a V3-Containing HIV-1 gp120 Core
inferredcites →https://doi.org/10.1126/science.1175868openalex-snapshot
Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120
inferredcites →https://doi.org/10.1126/science.1178746openalex-snapshot
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
inferredcites →https://doi.org/10.1126/science.1187659openalex-snapshot
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
inferredcites →https://doi.org/10.1126/science.1192819openalex-snapshot
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
inferredcites →https://doi.org/10.1126/science.1207227openalex-snapshot
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
inferredcites →https://doi.org/10.1126/science.1207532openalex-snapshot
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
inferredcites →https://doi.org/10.1126/science.1213782openalex-snapshot
Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
inferredcites →https://doi.org/10.1126/science.1245625openalex-snapshot
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
inferredcites →https://doi.org/10.1126/science.1925547openalex-snapshot
Receptor-Mediated Activation of Immunodeficiency Viruses in Viral Fusion
inferredcites →https://doi.org/10.1126/science.aad2450openalex-snapshot
Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer
inferredcites →https://doi.org/10.1126/science.aae0474openalex-snapshot
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
inferredcites →https://doi.org/10.1126/science.aaf0972openalex-snapshot
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
inferredcites →https://doi.org/10.1126/science.aaf1279openalex-snapshot
Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo
inferredcites →https://doi.org/10.1126/scitranslmed.3008992openalex-snapshot
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
inferredcites →https://doi.org/10.1126/scitranslmed.aad5752openalex-snapshot
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
inferredcites →https://doi.org/10.1128/aac.00150-07openalex-snapshot
A Novel Fluorescence Intensity Screening Assay Identifies New Low-Molecular-Weight Inhibitors of the gp41 Coiled-Coil Domain of Human Immunodeficiency Virus Type 1
inferredcites →https://doi.org/10.1128/aac.00376-10openalex-snapshot
Potent Strategy To Inhibit HIV-1 by Binding both gp120 and gp41
inferredcites →https://doi.org/10.1128/aac.00976-09openalex-snapshot
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and LongIn VivoHalf-Life
inferredcites →https://doi.org/10.1128/aac.01211-08openalex-snapshot
SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
inferredcites →https://doi.org/10.1128/aac.41.7.1521openalex-snapshot
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
inferredcites →https://doi.org/10.1128/aac.48.2.423-429.2004openalex-snapshot
Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542
inferredcites →https://doi.org/10.1128/jvi.00168-09openalex-snapshot
Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains
inferredcites →https://doi.org/10.1128/jvi.00196-11openalex-snapshot
Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic
inferredcites →https://doi.org/10.1128/jvi.00288-17openalex-snapshot
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly PotentIn Vitro,Ex Vivo, andIn VivoAntiviral Activity
showing the first 200 of 264 · page through all 264
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4830433openalex-extracted
Antimicrobial Peptide: An Attractive Therapeutic to Combat Antimicrobial Resistance
inferred← citeshttps://doi.org/10.1002/cbic.202100417openalex-snapshot
Systematic Evaluation of Fluorination as Modification for Peptide‐Based Fusion Inhibitors against HIV‐1 Infection
inferred← citeshttps://doi.org/10.1007/s00018-021-03759-0openalex-snapshot
Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs)
inferred← citeshttps://doi.org/10.1007/s00232-020-00136-zopenalex-snapshot
Entry Inhibitors: Efficient Means to Block Viral Infection
inferred← citeshttps://doi.org/10.1007/s00705-026-06669-3openalex-snapshot
The role of DPP4 in viral infections: from receptor biology to antiviral target
inferred← citeshttps://doi.org/10.1007/s10989-023-10524-3openalex-snapshot
Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics
inferred← citeshttps://doi.org/10.1007/s11517-023-02950-8openalex-snapshot
Inactivation of cell-free HIV-1 by designing potent peptides based on mutations in the CD4 binding site
inferred← citeshttps://doi.org/10.1007/s12274-023-5856-yopenalex-snapshot
UM15 reinforces a lymphocyte-mimicking nanotrap for precise HIV-1 inhibition
inferred← citeshttps://doi.org/10.1016/b978-0-12-814515-9.00126-0openalex-snapshot
Antiviral Classification
inferred← citeshttps://doi.org/10.1016/b978-0-443-18611-0.00015-2openalex-snapshot
Peptide and peptide-based drugs
inferred← citeshttps://doi.org/10.1016/j.antiviral.2025.106187openalex-snapshot
Pharmacokinetic and safety evaluation of lipopeptide-based HIV fusion inhibitor Lipovirtide in rats
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.114078openalex-snapshot
Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view
inferred← citeshttps://doi.org/10.1016/j.indcrop.2024.119855openalex-snapshot
Bringing bioactive peptides into drug discovery: Challenges and opportunities for medicinal plants
inferred← citeshttps://doi.org/10.1016/j.isci.2020.101785openalex-snapshot
Class IV Lasso Peptides Synergistically Induce Proliferation of Cancer Cells and Sensitize Them to Doxorubicin
inferred← citeshttps://doi.org/10.1016/j.micinf.2024.105366openalex-snapshot
Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure
inferred← citeshttps://doi.org/10.1016/j.molstruc.2025.141540openalex-snapshot
Synthesis of substituted arylsulphonamoyl ‘Leu-Gly’ dipeptide carboxamide derivatives containing antimalarial and other related diseases pharmacological properties
inferred← citeshttps://doi.org/10.1016/j.peptides.2020.170402openalex-snapshot
Peptides to combat viral infectious diseases
inferred← citeshttps://doi.org/10.1016/j.ymthe.2026.01.006openalex-snapshot
Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.1c00292openalex-snapshot
Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00781openalex-snapshot
A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00116openalex-snapshot
Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c01728openalex-snapshot
Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration
inferred← citeshttps://doi.org/10.1021/acsomega.1c00033openalex-snapshot
Fejerlectin, a Lectin-like Peptide from the Skin of Fejervarya limnocharis, Inhibits HIV-1 Entry by Targeting Gp41
inferred← citeshttps://doi.org/10.1021/jacs.5c22670openalex-snapshot
Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry
inferred← citeshttps://doi.org/10.1038/s41392-022-00904-4openalex-snapshot
Therapeutic peptides: current applications and future directions
inferred← citeshttps://doi.org/10.1038/s41423-024-01144-yopenalex-snapshot
gp120-derived amyloidogenic peptides form amyloid fibrils that increase HIV-1 infectivity
inferred← citeshttps://doi.org/10.1039/9781788016858-00001openalex-snapshot
Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets
inferred← citeshttps://doi.org/10.1063/5.0163137openalex-snapshot
Emerging bioactive antiviral drugs in the light of epidemics
inferred← citeshttps://doi.org/10.1080/17513758.2022.2113828openalex-snapshot
Analysis of HIV latent infection model with multiple infection stages and different drug classes
inferred← citeshttps://doi.org/10.1186/s12985-025-02794-8openalex-snapshot
Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report
inferred← citeshttps://doi.org/10.1248/cpb.c23-00891openalex-snapshot
Late-Stage Derivatization of Oleanolic Acid-Based Anti-HIV-1 Compounds
inferred← citeshttps://doi.org/10.1515/jib-2023-0053openalex-snapshot
Designing an optimized theta-defensin peptide for HIV therapy using in-silico approaches
inferred← citeshttps://doi.org/10.2174/012210299x255078231011111629openalex-snapshot
Fostemsavir: A Novel CD4 Attachment Inhibitor for Heavily Treated HIV-1 Patient
inferred← citeshttps://doi.org/10.3389/fcimb.2022.880030openalex-snapshot
Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection
inferred← citeshttps://doi.org/10.3389/fcimb.2025.1720027openalex-snapshot
Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance
inferred← citeshttps://doi.org/10.3389/fmed.2022.1036874openalex-snapshot
Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach
inferred← citeshttps://doi.org/10.3389/fphar.2020.603830openalex-snapshot
3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor
inferred← citeshttps://doi.org/10.3390/antib8040053openalex-snapshot
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
inferred← citeshttps://doi.org/10.3390/biom11040566openalex-snapshot
Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity
inferred← citeshttps://doi.org/10.3390/biom15030378openalex-snapshot
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?
inferred← citeshttps://doi.org/10.3390/biom16091221openalex-snapshot
Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies
inferred← citeshttps://doi.org/10.3390/cells15181704openalex-snapshot
Bicistronic Lentiviral Architecture Increases Surface Density of Membrane-Associated HIV Entry Inhibitors and Confers Tropism-Independent Protection to Modified Cells
inferred← citeshttps://doi.org/10.3390/microorganisms9020228openalex-snapshot
HIV-1 Entry and Prospects for Protecting against Infection
inferred← citeshttps://doi.org/10.3390/molecules26175305openalex-snapshot
Novel Antiretroviral Therapeutic Strategies for HIV
inferred← citeshttps://doi.org/10.3390/molecules29204951openalex-snapshot
The Role of Peptides in Combatting HIV Infection: Applications and Insights
inferred← citeshttps://doi.org/10.3390/pathogens15010032openalex-snapshot
Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins
inferred← citeshttps://doi.org/10.3390/pharmaceutics18080938openalex-snapshot
Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides
inferred← citeshttps://doi.org/10.3390/v12030326openalex-snapshot
Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
inferred← citeshttps://doi.org/10.3390/v13050735openalex-snapshot
HIV-1 Entry and Membrane Fusion Inhibitors
inferred← citeshttps://doi.org/10.3390/v15010107openalex-snapshot
The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles
inferred← citeshttps://doi.org/10.3410/f.739484140.793583073openalex-snapshot
Faculty Opinions recommendation of Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs).
inferred← citeshttps://doi.org/10.48550/arxiv.2102.03876openalex-snapshot
In silico model of infection of a CD4(+) T-cell by a human immunodeficiency type 1 virus, and a mini-review on its molecular pathophysiology
inferred← citeshttps://doi.org/10.64898/2026.04.20.719566openalex-snapshot
A narrow thermodynamic design window governs selective membrane permeabilization and antiviral activity of amphipathic peptides
inferred← citeshttps://doi.org/10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8openalex-snapshot
Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
inferred← citeshttps://doi.org/10.70675/c19636d1z1197z46d5z8c67z80971b27db3bopenalex-snapshot
Régulation métabolique de l'infection des cellules T CD4 par VIH-1 : vers de nouvelles cibles thérapeutiques
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.